Research Guide
How to read biotech licensing deals
Upfront payments, milestones, royalties, option structures, territory rights, and development responsibilities reveal how partners allocate risk and value. The headline number is rarely the full story.
What to check first
Start with the evidence that can change value: clinical relevance, regulatory path, competitive context, financing needs, and whether the company can reach the next milestone.
How Drugnews uses this guide
We apply these frameworks when writing company research, paid analysis, and client-facing content so that readers can follow the logic behind each judgment.